Sodium Valproate | CAS No. 1069-66-5 | Active Pharma Ingredient (API)

Sodium valproate is an Active Pharmaceutical Ingredient (API) with the CAS No. 1069-66-5. It is the sodium salt of valproic acid, which is commonly used to treat epilepsy, bipolar disorder, and migraine headaches.

Sodium valproate works by increasing the levels of a neurotransmitter called GABA (gamma-aminobutyric acid) in the brain, which helps to reduce seizure activity and stabilize mood. It is usually taken orally in the form of tablets or syrup, and the dosage and duration of treatment depend on the individual’s condition and medical history.

Sodium valproate is effective in treating various types of epilepsy, including generalized seizures, absence seizures, myoclonic seizures, and partial seizures. It can also be used in combination with other medications to control seizures that are difficult to treat.

However, like all medications, sodium valproate has some potential side effects, including nausea, vomiting, drowsiness, dizziness, hair loss, weight gain, tremors, and liver damage. It may also interact with other medications, so it is important to consult a healthcare professional before taking this medication.

Sodium valproate is classified as a Schedule 4 substance under the Australian Poisons Standard, indicating that it has a low potential for abuse or dependence. However, it is important to use this medication only as prescribed and to follow the recommended dosage and administration instructions.

Overall, sodium valproate is a commonly used and effective treatment for epilepsy and other neurological disorders, but it is important to monitor patients closely for any adverse effects and adjust the dosage as necessary. Regular medical check-ups and monitoring of blood levels may be required to ensure the medication is working effectively and safely.